• Depot
  • Watchlist
  • Glocke
  • Handeln

    • Sangamo Therapeutics Inc News

    0,4845 € +3,09% +0,0145 €
    26.04.24 23:00:20 L&S RT aktualisieren | Orderbuch | Mehr Kurse »
    WKN: 936386
    ISIN: US8006771062
    US-Symbol: SGMO
    Typ: Aktie

    Sangamo Therapeutics Inc News

    22.04.24 - Businesswire
    Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
    Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 20 ...
    22.03.24 - Businesswire
    Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
    Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, ...
    13.03.24 - Businesswire
    Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
    Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial results, ...
    13.03.24 - Businesswire
    Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
    Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preclinical data from its proprietary adeno-​associated virus (AAV) capsid variant, ...
    12.03.24 - Businesswire
    Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
    Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its fourth quarter and full year 2023 ...
    12.02.24 - Businesswire
    Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
    Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced important U.S. and European regulatory updates for isaralgagene civaparvovec, or ...
    05.02.24 - Businesswire
    Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
    Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary data from the Phase 1/2 STAAR clinical study evaluating ...
    27.02.23 - PR Newswire
    Thinking about buying stock in Broadmark Realty Capital, Seagen, Sangamo Therapeutics, Li Auto, or Bed Bath & Beyond?
    Thinking about buying stock in Broadmark Realty Capital, Seagen, Sangamo Therapeutics, Li Auto, or Bed Bath & Beyond? PR Newswire
    20.09.21 - Der Aktionär
    Faule Äpfel im Korb: Die schlechtesten Empfehlungen aus dem Chart‑Check
    28.12.20 - Der Aktionär
    Sangamo: Favorit für 2021 nicht zu bremsen – 50 Prozent in wenigen Tagen
    11.12.20 - Der Aktionär
    Gen‑Schere‑Aktien Intellia, Editas Medicine und Co drehen durch: Sangamo schießt 53 Prozent nach oben
    19.03.20 - Aktiencheck
    Sangamo BioSciences: Mega-Deal mit Biogen und Pipeline-Fortschritte lassen die Aktie kalt - Aktienanalyse
    Kulmbach (www.aktiencheck.de) - Sangamo BioSciences-​Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen ...
    19.03.20 - Der Aktionär
    Gilead‑Partner Sangamo: CEO Sandy Macrae wirft einen Blick in die Zukunft
    09.03.20 - Der Aktionär
    Sangamo: Top‑Deal für Gen‑Schere‑Hoffnung
    09.03.20 - Aktiencheck
    Sangamo BioSciences: Hochinteressante, aber spekulative Depotbeimischung - Aktienanalyse
    Kulmbach (www.aktiencheck.de) - Sangamo BioSciences-​Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen ...
    08.03.20 - Der Aktionär
    Sangamo‑CEO zum Biogen‑Deal: "Immenses Potenzial"
    28.02.20 - Aktiencheck
    Sangamo BioSciences: Deal mit Biogen! Aktienanalyse
    Kulmbach (www.aktiencheck.de) - Sangamo BioSciences-​Aktienanalyse von "Der Aktionär": Marion Schlegel vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen ...
    28.02.20 - Der Aktionär
    Hammermeldung: US‑Biotech Sangamo mit gewaltigem Kurssprung – was ist da los?
    13.12.19 - Der Aktionär
    Sangamo: So geht es jetzt beim heißen Biotech‑Eisen weiter – CMO im Exklusiv‑Interview
    19.10.19 - Der Aktionär
    Gilead‑Partner Sangamo: "Bisher sehen die Daten vielversprechend aus"

    Newssuche

    Videos

    newspaper
    26.04.24 +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »